Evidence map›Paper›PMID 35429246›Full record

Trial reportCancer immunology, immunotherapy : CII2022

Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.

Yasuhiro Nagata, Shinichi Kageyama, Takeshi Ishikawa, Satoshi Kokura, Tetsuya Okayama, Tetsuya Abe, Masahiko Murakami, Koji Otsuka, Tomotake Ariyoshi, Takashi Kojima and 34 more

Open access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Low-frequency CD8NPJ vaccines · 2024
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors at 18 institutions in 1 country.

Yasuhiro NagataLeading Medical Research Core Unit, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Shinichi KageyamaDepartment of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan. kageyama@med.mie-u.ac.jp.ORCID http://orcid.org/0000-0002-7682-3295
Takeshi IshikawaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Satoshi KokuraDepartment of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tetsuya OkayamaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tetsuya AbeDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Masahiko MurakamiDivision of Gastroenterological and General Surgery, School of Medicine, Showa University, Tokyo, Japan.
Koji OtsukaDivision of Gastroenterological and General Surgery, School of Medicine, Showa University, Tokyo, Japan.
Tomotake AriyoshiDivision of Gastroenterological and General Surgery, School of Medicine, Showa University, Tokyo, Japan.
Takashi KojimaDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Hospital East, Kashiwa, Japan.
Ken TaniguchiDepartment of Surgery, Nagasaki Medical Center, Omura, Japan.
Shinichiro KobayashiDepartment of Surgery, Nagasaki Medical Center, Omura, Japan.
Hideaki ShimadaDepartment of Gastroenterological Surgery, Toho University Omori Medical Center, Tokyo, Japan.
Satoshi YajimaDepartment of Gastroenterological Surgery, Toho University Omori Medical Center, Tokyo, Japan.
Takashi SuzukiDepartment of Gastroenterological Surgery, Toho University Omori Medical Center, Tokyo, Japan.
Satoshi HiranoDepartment of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Takahiro TsuchikawaDepartment of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Toshiaki ShichinoheDepartment of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Shugo UedaDepartment of Gastroenterological Surgery and Oncology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
Kengo KanetakaDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Akira YonedaDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hisashi WadaDepartment of Clinical Research in Tumor Immunology, Osaka University Graduate School of Medicine, Suita, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Hiroki YamaueSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Masahiro KatsudaSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Masaki OhiDepartment of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
Hiromi YasudaDepartment of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
Ken KondoDepartment of Surgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Masato KataokaDepartment of Surgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Yasuhiro KoderaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masahiko KoikeDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Taizo ShiraishiDepartment of Oncologic Pathology, Mie University Graduate School of Medicine, Tsu, Japan.
Yoshihiro MiyaharaDepartment of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan.
Naoki GoshimaDepartment of Human Science, Faculty of Human Science, Musashino University, Tokyo, Japan.
Eriko FukudaCellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.
Kei YamaguchiMolecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.
Eiichi SatoDepartment of Pathology (Medical Research Center), Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Hiroaki IkedaDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Tomomi YamadaDepartment of Medical Innovation, Osaka University Hospital, Suita, Japan.
Masaharu OsakoFIVERINGS CO., LTD., Osaka, Japan.
Kaoru HiraiFIVERINGS CO., LTD., Osaka, Japan.
Hiroshi MiyamotoFIVERINGS CO., LTD., Osaka, Japan.
Takashi WatanabeDepartment of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan.
Hiroshi ShikuDepartment of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan. shiku@med.mie-u.ac.jp.
Mie University · JPNagasaki University · JPHokkaido University · JPKyoto Prefectural University of Medicine · JPShowa University · JPToho University · JPNagasaki Medical Center · JPNagoya University · JPNational Hospital Organization · JPNational Institute of Advanced Industrial Science and Technology · JPThe University of Osaka · JPWakayama Medical University · JPAichi Cancer Center · JPKitano Hospital · JPMusashino University · JPNational Cancer Center Hospital East · JPOsaka University Hospital · JPTokyo Medical University · JP

Funding

Japan Agency for Medical Research and Development JP17ck0106143
6 · The paper itself

Abstract

The aim of this study was to determine the efficacy and the biomarkers of the CHP-NY-ESO-1 vaccine complexed with full-length NY-ESO-1 protein and a cholesteryl pullulan (CHP) in patients with esophageal squamous cell carcinoma (ESCC) after surgery. We conducted a randomized phase II trial. Fifty-four patients with NY-ESO-1-expressing ESCC who underwent radical surgery following cisplatin/5-fluorouracil-based neoadjuvant chemotherapy were assigned to receive either CHP-NY-ESO-1 vaccination or observation as control. Six doses of CHP-NY-ESO-1 were administered subcutaneously once every two weeks, followed by nine more doses once every four weeks. The endpoints were disease-free survival (DFS) and safety. Exploratory analysis of tumor tissues using gene-expression profiles was also performed to seek the biomarker. As there were no serious adverse events in 27 vaccinated patients, we verified the safety of the vaccine. DFS in 2 years were 56.0% and 58.3% in the vaccine arm and in the control, respectively. Twenty-four of 25 patients showed NY-ESO-1-specific IgG responses after vaccination. Analysis of intra-cohort correlations among vaccinated patients revealed that 5% or greater expression of NY-ESO-1 was a favorable factor. Comprehensive analysis of gene expression profiles revealed that the expression of the gene encoding polymeric immunoglobulin receptor (PIGR) in tumors had a significantly favorable impact on outcomes in the vaccinated cohort. The high PIGR-expressing tumors that had higher NY-ESO-1-specific IgA response tended to have favorable prognosis. These results suggest that PIGR would play a major role in tumor immunity in an antigen-specific manner during NY-ESO-1 vaccinations. The IgA response may be relevant.

Indexed as

Cancer VaccinesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaReceptors, Polymeric ImmunoglobulinAntibodies, NeoplasmAntigens, NeoplasmCisplatinFluorouracilGlucansHumansImmunoglobulin AImmunoglobulin GMembrane ProteinsPrognosisAntibodies, NeoplasmAntigens, NeoplasmCancer VaccinesCisplatinFluorouracilGlucansImmunoglobulin AImmunoglobulin GMembrane ProteinspullulanReceptors, Polymeric ImmunoglobulinCancer vaccineEsophageal cancerNY-ESO-1 antigenPIGR gene

Identifiers

PMID35429246
PMCPMC10992970
OpenAlexW4223888858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.